134379-77-4

134379-77-4 structure

Name: Dexelvucitabine
Chemical Name: 4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
CAS Number: 134379-77-4
Molecular Formula: C₉H₁₀FN₃O₃
Molecular Weight: 227.19200
Catalog: Signaling Pathways Anti-infection HIV
Create Date: 2016-11-26 08:28:33
Modify Date: 2026-07-16 16:22:17
Dexelvucitabine (Reverset; d-d4FC), a Cytidine (HY-B0158) analog, is an orally active nucleoside reverse transcriptase inhibitor. Dexelvucitabine is a powerful drug against HIV-1-resistant viruses containing a thymidine analog and/or M184V mutation in the viral polymerase. Dexelvucitabine is a 2′-Deoxycytidine antiretroviral agent[1].

Name	4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
Synonyms	DFC 2’,3’-Dideoxy-2’,3’-didehydro-5-fluoro-cytidine, FddddC, Dexelvucitabine (DFC), Reverset Reverset beta-D-D-4FC Inhibitor,thymidine,Human immunodeficiency virus,d-d4FC,cytidine,M184V mutation,antiretroviral,inhibit,Reverset,2′-deoxycytidine,viral polymerase,Dexelvucitabine,HIV,resistant viruse,nucleoside reverse transcriptase,HIV-1,Reverse Transcriptase Dexelvucitabine, 10 mM in DMSO 5-Fluoro-1-(2',3'-dideoxy-2',3'-didehydro-b-D-abinofuranosyl)-cytosine 2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine Cytidine,2',3'-didehydro-2',3'-dideoxy-5-fluoro INCB-8721 5-Fluoro-1-(2’,3’-dideoxy-2’,3’-didehydro-β-D-abinofuranosyl)-cytosine (Dexelvucitabine) 2',3'-didehydro-2,3-dideoxy-5-fluorocytidine D-D4FC DPC-817 2',3'-didehydro-2',3'-dideoxy-5-fluoroCytidine D-D-4FC YZ-817 4-AMINO-5-FLUORO-1-[(2R,5S)-5-(HYDROXYMETHYL)-2,5-DIHYDROFURAN-2-YL]PYRIMIDIN-2(1H)-ONE

Description	Dexelvucitabine (Reverset; d-d4FC), a Cytidine (HY-B0158) analog, is an orally active nucleoside reverse transcriptase inhibitor. Dexelvucitabine is a powerful drug against HIV-1-resistant viruses containing a thymidine analog and/or M184V mutation in the viral polymerase. Dexelvucitabine is a 2′-Deoxycytidine antiretroviral agent[1].
Related Catalog	Signaling Pathways >> Anti-infection >> HIV Research Areas >> Infection Signaling Pathways >> Anti-infection >> Reverse Transcriptase
Target	HIV-1
In Vivo	Dexelvucitabine (Reverset; d-d4FC; 33.3 mg/kg by i.v. or p.o.) has distribution and elimination half-lives (t1/2α and t1/2β, respectively) of 0.7 and 3.6 h in monkeys, respectively. The Cmax ranges from 21.1 to 47.5 μM[2]. Dexelvucitabine has a favorable pharmacokinetic profile with a long half-life (4.71 and 10.75 h after administration by the intravenous [i.v.] and oral [p.o.] routes, respectively) in woodchucks[2].
References	[1]. Brenda I Hernandez-Santiago, et al. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. Antimicrob Agents Chemother. 2007 Jun;51(6):2130-5. [2]. L Ma, et al. Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrob Agents Chemother. 1999 Feb;43(2):381-4.